ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq: ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Kevin Brodbeck, ...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq:ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 1, 2025 ( the "Grant ...
Oric Pharmaceuticals, Inc. ( ORIC ) Now Trades Above Golden Cross: Time to Buy?
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Oric Pharmaceuticals, Inc. ( ORIC ) is a Great Momentum Stock: Should You Buy?
Does Oric Pharmaceuticals, Inc. (ORIC) have what it takes to be a top stock pick for momentum investors? Let's find out.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 03, 2025 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq:ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on July 1, 2025 ( the "Grant ...
All You Need to Know About Oric Pharmaceuticals ( ORIC ) Rating Upgrade to Buy
Oric Pharmaceuticals (ORIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does Oric Pharmaceuticals ( ORIC ) Have the Potential to Rally 104.99% as Wall Street Analysts Expect?
The consensus price target hints at a 105% upside potential for Oric Pharmaceuticals (ORIC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
What Makes Oric Pharmaceuticals, Inc. ( ORIC ) a Strong Momentum Stock: Buy Now?
Does Oric Pharmaceuticals, Inc. (ORIC) have what it takes to be a top stock pick for momentum investors? Let's find out.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq:ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 2, 2025 ( the "Grant ...
Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals ( ORIC ) : Here's What You Should Know
The consensus price target hints at a 131.3% upside potential for Oric Pharmaceuticals (ORIC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results - Alzamend Neuro ( NASDAQ:ALZN ) , Best Buy Co ( NYSE:BBY )
U.S. stocks traded mostly higher midway through trading, with the S&P 500 gaining around 0.4% on Thursday. The Dow traded up 0.03% to 42,113.07 while the NASDAQ jumped 0.59% to 19,213.22. The S&P 500 also rose, gaining, 0.37% to 5,910.10. Real estate shares jumped by 0.9% on Thursday.
ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study
ORIC Pharmaceuticals stock rises 20% pre-market on early data showing strong PSA responses and tolerability for prostate cancer drug ORIC-944 in phase Ib study.
ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital - ORIC Pharmaceuticals ( NASDAQ:ORIC )
59% of mCRPC patients saw a PSA50 response; 47% confirmed after 1 month. ORIC raised $125 million in a private placement, extending cash into 2H 2027. Unlock your all-in-one trading dashboard with real-time alerts, rankings, and stock ideas-60% off ends soon. ORIC Pharmaceuticals Inc.
Veeva Systems, e.l.f. Beauty, C3.ai, BRP And Other Big Stocks Moving Higher On Thursday - Agilent Technologies ( NYSE:A ) , C3.ai ( NYSE:AI )
U.S. stocks were mostly higher, with the Nasdaq Composite gaining around 100 points on Thursday. Shares of Veeva Systems Inc. VEEV rose sharply during Thursday's session following strong quarterly results. The company reported adjusted earnings per share of $1.97, beating the analyst consensus ...
Why Nvidia Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket - C3.ai ( NYSE:AI ) , Actelis Networks ( NASDAQ:ASNS )
Shares of NVIDIA Corporation NVDA rose sharply in today's pre-market trading after the company posted first-quarter results. The company reported first-quarter revenue of $44.1 billion, up 69% year-over-year and up 12% from the fourth quarter. The revenue beat a Street consensus estimate of $43.2 ...
ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing
Financing led by SR One and includes participation from new and existing investors, including Point72, Viking Global Investors, Venrock Healthcare Capital Partners, New Enterprise Associates ( NEA ) , Nextech, Vivo Capital, and NEXTBio Capital ...
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq: ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in ...
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - ORIC Pharmaceuticals ( NASDAQ:ORIC )
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ORIC, a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following ...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SOUTH SAN FRANCISCO Calif. and SAN DIEGO, May 02, 2025 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq:ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on May 1, 2025 ( the "Grant Date" ) ...
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research ( AACR ) Annual Meeting - ORIC Pharmaceuticals ( NASDAQ:ORIC )
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 28, 2025 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc.
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research ( AACR ) Annual Meeting
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 28, 2025 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq: ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the presentation of a poster at the ...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 04, 2025 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq:ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on April 1, 2025 ( the "Grant ...
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 31, 2025 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq: ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in ...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 07, 2025 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq:ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on March 3, 2025 ( the "Grant ...
ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones
Anticipated registrational development plans for ORIC-944 and ORIC-114 prioritized to focus on indications with strongest clinical validation and highest unmet need ...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 07, 2025 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq:ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on February 3, 2025 ( the "Grant ...
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 27, 2025 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq: ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in ...
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - ORIC Pharmaceuticals ( NASDAQ:ORIC )
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 27, 2025 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ORIC, a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following ...
H&E Equipment Services, ACM Research, Robinhood And Other Big Stocks Moving Higher On Tuesday - ACM Research ( NASDAQ:ACMR ) , Applied Digital ( NASDAQ:APLD )
U.S. stocks were higher, with the Dow Jones index gaining over 100 points on Tuesday. Shares of H&E Equipment Services, Inc. HEES rose sharply during Monday's session after the company inked a deal to be acquired by United Rentals, Inc. URI for around $4.8 billion, including $1.4 billion in net ...
ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones
Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients with ...
PriceSmart Posts Weak Earnings, Joins Roku And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Mercury General ( NYSE:MCY ) , NatWest Group ( NYSE:NWG )
U.S. stock futures were slightly lower this morning, with the Dow futures falling around 0.1% on Friday. Shares of PriceSmart, Inc. PSMT fell sharply in today's pre-market trading after the company reported worse-than-expected first-quarter EPS results.
ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 06, 2025 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq: ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob M.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 03, 2025 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq:ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on January 2, 2025 ( the "Grant ...
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO and SAN DIEGO, Nov. 25, 2024 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq: ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the ...
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - ORIC Pharmaceuticals ( NASDAQ:ORIC )
SOUTH SAN FRANCISCO and SAN DIEGO, Nov. 25, 2024 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ORIC, a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor ...
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
Hoerter Brings Over Three Decades of Oncology Commercialization and Leadership Experience ...
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - ORIC Pharmaceuticals ( NASDAQ:ORIC )
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 04, 2024 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ORIC, a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following ...
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - ORIC Pharmaceuticals ( NASDAQ:ORIC )
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 01, 2024 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc.
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 01, 2024 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq:ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on November 1, 2024 ( the "Grant ...
ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - ORIC Pharmaceuticals ( NASDAQ:ORIC )
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 09, 2024 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc.
ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 09, 2024 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq: ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present a ...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 04, 2024 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq:ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 1, 2024 ( the "Grant ...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 06, 2024 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq:ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 3, 2024 ( the ...
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 26, 2024 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq: ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in ...
ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs - ORIC Pharmaceuticals ( NASDAQ:ORIC )
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 05, 2024 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ORIC, a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Keith Lui as Senior Vice ...
ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 05, 2024 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq: ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Keith Lui as ...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - ORIC Pharmaceuticals ( NASDAQ:ORIC )
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 02, 2024 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 02, 2024 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq:ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 1, 2024 ( the "Grant ...
ORIC Pharmaceuticals ( ORIC ) Up on Collaboration With Bayer & JNJ
ORIC Pharmaceuticals (ORIC) teams up with Bayer and Johnson & Johnson for a phase I study on ORIC-944 in patients with metastatic prostate cancer. Its shares rise on the news.
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
ORIC-944, a potential best-in-class PRC2 inhibitor, is being evaluated in combination with darolutamide and in combination with apalutamide in patients with ...
